Calling for more scientific evidence
Dr. Colin Jacobs
Biomedical engineer Dr. Colin Jacobs explained the role AI can play in grading, automated lung nodule detection, and workflow in European national LCS programs. “The AI determines the type of nodule and measures its size and grade,” said Dr. Jacobs of Radboud University Medical Center Nijmegen.
According to him, there are 17 AI products related to lung nodule detection and characterization in Europe that are CE approved for clinical use. “We are seeing an increase in the use of AI in screening programs and clinical trials, but there is little to no reimbursement for AI support,” Jacobs said. He called for more scientific evidence by continuously monitoring the actual performance of AI in operation, conducting new studies to find appropriate models for how to pay for AI in LCS, and creating a reference database for quality control and quality assurance of AI products for LCS.
Pippa Powell, from Lungs Europe, a collaboration between the European Respiratory Society and the European Lung Foundation, described participant perspectives and outreach, giving as examples the SOLACE stakeholder forum, the Lung Cancer Advisory Group, websites, social media platforms, as well as advice materials and newsletters to disseminate information.
profile:
Radiologist Professor Helmut Prosch is from the Department of Biomedical Imaging and Image-Guided Therapy at the Medical University of Vienna and Vienna General Hospital, Austria. He is a chest/thorax specialist and specializes in AI, clinical IT, hybrid imaging, imaging techniques and molecular imaging principles.
Research scientist Dr Colin Jacobs is part of the Diagnostic Image Analysis group in the Medical Imaging Department at Radboud University Medical Centre Nijmegen, and is particularly interested in AI, chest/thoracic imaging and computer applications.
